Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

SBTi approves Fagerhult Group’s net-zero science-based targets

Fagerhult Group’s near and long-term targets have now been validated and approved by the Science Based Targets initiative (SBTi). The long-term target to become science-based net-zero is set to no later than 2045.Energy-efficiency is high on the agenda to reach the climate goals and the lighting industry has a part to play. Lighting accounts for up to 15 per cent of global energy consumption and by using the latest smart lighting solutions, users can potentially reduce energy consumption by up to 90 per cent. "We are very proud to have our targets validated and approved by the Science

Reaching New Heights: SOFTSWISS Game Aggregator Reveal Q3 2023 Results

In Q3 2023, the SOFTSWISS Game Aggregator  achieved a significant milestone, with 860 brands now connected, which marks a 90-brand increase from the first quarter. SOFTSWISS, an international technology company that has developed a complete product ecosystem for the iGaming industry, shares the accomplishments of its flagship product.This increase underscores the industry's strong demand for the Game Aggregator, known for its high-quality service and outstanding player engagement tools,

Asetek Presents Third Quarter 2023 Results on Thursday, 2 November

Asetek will release its financial results for the third quarter of 2023 on Thursday, 2 November at 12:00 CET. CEO André Sloth Eriksen and CFO Peter Dam Madsen will present the Company's results at 14:00 CET and invite investors, analysts and media to join the presentation. The presentation is expected to last up to one hour, including Q&A, and can be followed via live webcast or conference call. Webcast - audio and slide presentation: Please join the results webcast via the following link: https://events.q4inc.com/attendee/874100850 Conference call - audio only: Please dial

Record date and payment date of Metso’s second dividend instalment of EUR 0.15

Metso Corporation’s stock exchange release on October 26, 2023, at 16:15 p.m. EESTMetso’s Annual General Meeting (AGM) held on May 3, 2023, decided to pay the dividend for the financial year 2022 in two instalments. The Board of Directors has today confirmed that the payment date for the second dividend instalment of EUR 0.15 per share will be November 6, 2023, and the record date October 30, 2023.According to the AGM’s decision, the first dividend instalment of EUR 0.15 per share was paid on May 12, 2023. Further information, please contact: Juha Rouhiainen, VP, Investor Relations,

Form 8.3 - EMIS Group plc

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.         KEY INFORMATION (a) Full name of discloser: Magnetar Capital Partners LP(b) Owner or controller of interests and shortpositions disclosed, if different from 1(a):    The naming of nominee or vehicle companies isinsufficient.  For a trust, the trustee(s),settlor and beneficiaries must be named.(c) Name of offeror/offeree in relation to whose EMIS Group

Form 8.3 - Dechra Pharmaceuticals plc

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.         KEY INFORMATION (a) Full name of discloser: Magnetar Capital Partners LP(b) Owner or controller of interests and shortpositions disclosed, if different from 1(a):    The naming of nominee or vehicle companies isinsufficient.  For a trust, the trustee(s),settlor and beneficiaries must be named.(c) Name of offeror/offeree in relation to whose Dechra

Notification in accordance with the Finnish Securities Market Act Chapter 9 § 5: BlackRock, Inc.’s holding in Wärtsilä Corporation

Wärtsilä Corporation, flagging notification, 26 October 2023 at 16:00 EESTNotification in accordance with the Finnish Securities Market Act Chapter 9 § 5: BlackRock, Inc.’s holding in Wärtsilä CorporationBlackRock, Inc. has informed Wärtsilä Corporation that it has crossed below the 5% disclosure limit on total holding in shares and voting rights on 25 October 2023. Following the transaction, BlackRock, Inc. owns 4.99% of Wärtsilä’s shares and voting rights, while its total holding in Wärtsilä Corporation corresponds to 5.26%. Total position of BlackRock, Inc. and its funds subject to

Cline and Professor Anna Ström are granted support for a joint doctoral student

Cline Scientific AB (publ) ("Cline" or the "Company") together with Professor Anna Ström at Chalmers University of Technology is given the opportunity for a joint SSF Industrial PhD student.The “Stiftelsen för Strategisk Forskning” (The Foundation for Strategic Research), SSF, finances research in natural science, technology, and medicine with approximately SEK 700 million a year. The purpose of the Industrial PhD program is to contribute to excellent research within SSF's areas of interest. The research shall promote cross-fertilization between academia and industry and contribute to the

Invitation to presentation of third quarter 2023 results

Norse Atlantic ASA welcomes to a presentation of its 3Q 2023 financial report on Wednesday, November 1st at 10:00 am. The presentation will be held at the offices of Pareto Securities (11th floor, Dronning Mauds Gate 3, 0250 Oslo, Norway).The financial report for 3Q 2023 will be released in the evening of Tuesday 31 October. For further information, please contact: Anders Hall Jomaas (Chief Financial Officer) +47 912 40 945, anders.jomaas@flynorse.com Arendal, October 26th, 2023 Norse Atlantic ASA This information is subject of the disclosure requirements pursuant to

Bittium Partners with ResMed to Offer Advanced Home Sleep Apnea Test and Analysis to Hospitals and Care Centers

Bittium CorporationPress Release Bittium Partners with ResMed to Offer Advanced Home Sleep Apnea Test and Analysis to Hospitals and Care Centers Bittium Corporation, Press Release on October 26, 2023, at 3.00 p.m. (CEST +1) Bittium Biosignals Ltd, a subsidiary of Bittium Corporation, and ResMed have signed an agreement under which ResMed becomes a distributor of Bittium Respiro™ the advanced Home Sleep Apnea Test and Analysis Solution. The solution includes Bittium Respiro™ measuring device and its accessories, as well as Bittium Respiro Analyst™ software analysing tool and

BULTEN'S Q3 REPORT 2023

A quarter of higher sales and ongoing capacity challenges – although acquisitions create opportunitiesTHIRD QUARTER · Net sales amounted to SEK 1,378 (1,095) million, an increase of 25.9% on the same period the previous year. · Operating earnings (EBIT) totaled SEK 31 (47) million, equating to an operating margin of 2.3% (4.3). · Adjusted operating earnings totaled SEK 36 (47) million, equating to an adjusted operating margin of 2.6% (4.3). Operating earnings have been charged with transaction costs of SEK -5 million attributable to the acquisition of Exim & Mfr Holdings Pte Ltd (

Capsol Technologies: Conversion to ASA completed – new name of the company

Oslo, Norway - 10 October 2023An extraordinary general meeting of Capsol Technologies was held on Wednesday 27September 2023 resolving on a conversion from AS to ASA. Today, the conversionhas been completed and registered in the Norwegian Register of BusinessEnterprises.The new name of the company is Capsol Technologies ASA.For further information, please contact:Ingar BerghChief Financial Officer, Capsol Technologies+47 926 20 330ingar.bergh@capsoltechnologies.comAbout Capsol TechnologiesCapsol Technologies is a carbon capture technology provider with a goal to

Cereno Scientific assists the Swedish Economic Crime Authority

Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that the company has been informed that the Swedish Economic Crime Authority (ECA) has initiated a preliminary investigation related to a suspected insider trade on the Swedish stock market. Cereno has currently no information on whether this investigation concerns the Cereno Scientific’s share or other shares traded on the stock market. Cereno Scientific is assisting the authorities in their investigation.No employee, member of the

iLOQ launches its battery-free product portfolio for the North American multifamily property market

iLOQ is a technology disruptor that has transformed mechanical locking into highly functional, secure and sustainable digital access management. Our battery-free smart locks and keyless cellphone-based solutions provide benefits for building owners, property managers and residents alike by maximizing security, minimizing maintenance, administration and lifecycle costs, and creating smart living in multifamily properties. This year, we are celebrating our 20th anniversary. That’s two decades of innovating battery-free solutions that have completely revolutionized the landscape

Observe Medical - First shipment of UnoMeter[TM] 500 products

Oslo, October 26, 2023 - Observe Medical ("the Company" or "Observe Medical") today announces the shipment of the first UnoMeter[TM] 500 products to distributors in Poland and Spain. Containers carrying over 96,000 UnoMeterTM 500 products are now loaded at our OEM factory and set to ship on October 30th, which build upon the previous stock announcement regarding signed orders for UnoMeterTM products. The Company expects continuous deliveries to the European market throughout the fourth quarter of this year. “We are excited to finally begin the delivery of UnoMeterTM 500 products to

Baptist Health Lexington selects RayStation

RaySearch Laboratories AB (publ) announces that Baptist Health Lexington, Kentucky, USA, has begun implementation of the treatment planning system RayStation®*.RayStation will be used to treat patients at Baptist Health Lexington as well as Baptist Health Hamburg. It will be used to plan for a wide range of delivery systems, including linear accelerators from Elekta and Varian as well as CyberKnife and Tomotherapy from Accuray. RayStation will also be used for high dose rate brachytherapy planning. The configuration includes advanced features such as fallback planning, multi-criteria

Finnair Cargo takes a step towards self-sufficient energy production

Finnair Cargo is making a move towards fully self-sustainable energy production in November – just in time to celebrate Finnair’s 100th birthday. Throughout the summer and autumn months, Finnair Cargo has installed an additional 1790 solar panels to the roof of its COOL Nordic Cargo Hub at Helsinki Airport in Finland. These join 1200 panels installed when the terminal was originally constructed and provide enough energy on sunny days to sustain the cargo space in full and feed surplus energy to other Finnair facilities.   “With this addition, the COOL Nordic Cargo Hub will be the third

Quick Tips on How to Make Your Home More Energy-Efficient

When your home is more energy-efficient, this leads to lower bills and a reduced carbon footprint. There are many things you can do to make your home more energy efficient. From upgrading your lighting to ensuring your appliances are clean, so many things can assist in making sure you cut down your energy bills, so you're paying as little as possible. This is very important during the winter months when you tend to spend more due to heating and spending more time indoors.   [A person working on a wall Description automatically generated]   Energy expert William Hobbs at

Scila AB Secures Coveted Spot in the Chartis RiskTech100, 2024

Stockholm, October 25[th], 2023 - Scila, a prominent name in the international financial markets monitoring sector, is proud to announce its inclusion in the highly esteemed Chartis RiskTech100 for the year 2024. This recognition is a testament to Scila's relentless commitment to providing cutting-edge solutions in the risk management domain.The Chartis RiskTech100 is an annual report that evaluates and ranks technology providers in the risk and compliance industry. Being featured in this prestigious list underlines Scila's position as a frontrunner in delivering innovative and

Qt Group Plc updates its long-term targets and aims to double its net sales by 2027

Qt Group Plc, Stock Exchange Release, October 26, 2023 at 1:05pm EESTAt its meeting on October 26, 2023, the Board of Directors of Qt Group Plc has decided to update the company’s financial targets for the new strategy period until 2027.  According to the decision of the Board of Directors, the company’s targets for the new strategy period until 2027 are as follows: · annual net sales growth of 20–30%, which means that the company will more than double its net sales over the next four years · an operating profit margin (EBITA %) of at least 25% Exchange rate fluctuations will

Third quarter 2023: Revenue growth weaker than estimated, operating profit enhanced from the comparison period

Qt Group Plc, stock exchange release, October 26, 2023 at 1.00 pm EEST This release is a summary of Qt Group Plc’s Interim Statement for January-September 2023. The complete report is attached to this release as a PDF file, and it is also available on the company's website at www.qt.io/investorsJuly-September 2023  · Net sales increased 7.7 percent to EUR 38.0 million (EUR 35.3 million). The effect of exchange rates on the comparison period’s net sales was EUR -1.7 million and at comparable exchange rates, net sales increased by 13.1 percent. · Operating profit (EBITA) was EUR

Follow-up study suggests Diamyd® may offer advantages in delaying type 1 diabetes onset

A retrospective follow-up study of two prior randomized placebo-controlled trials (DiAPREV-IT and DiAPREV-IT2) indicates numerical benefits, although not statistically significant, favoring treatment with only two subcutaneous injections of Diamyd[®] on reducing the incidence of type 1 diabetes diagnosis (Stage 3) in healthy children at risk of type 1 diabetes (Stage 1 or Stage 2) carrying the HLA DR3-DQ2 haplotype. The study, encompassing a total of 76 children, out of which 40 carried the HLA DR3-DQ2 haplotype, had a maximum follow-up time of 13 years and was performed by Professor Helena

There are no items matching the current filter
There are no more items matching the current filter
Back to top